Authorized purpose: ClariCT.AI assists radiologists and specialists by denoising and enhancing DICOM CT images of the head, chest, heart, and abdomen, including low-dose filtered-back-projection and iterative-reconstruction images, and transmitting processed images to a PACS workstation.
Clinical role
Post-processing analysis
Images and patients
CT/CTA · Head, chest, heart, and abdomen
Key limitation
Keep in mind: The indication is processing and enhancement of CT DICOM images; manufacturer neutrality is stated in the FDA indication.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: ClariCT.AI assists radiologists and specialists by denoising and enhancing DICOM CT images of the head, chest, heart, and abdomen, including low-dose filtered-back-projection and iterative-reconstruction images, and transmitting processed images to a PACS workstation.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head, chest, heart, and abdomen Input: DICOM CT images, including low-dose filtered-back-projection and iterative-reconstruction images from any CT scanner manufacturer/model within the labeled CT workflow.
Who uses it?Intended users: Radiologists and specialists.
What does the software produce?Output: Denoised and enhanced CT DICOM images transmitted to a PACS workstation.
What is its most important limitation?Key limitation: The indication is processing and enhancement of CT DICOM images; manufacturer neutrality is stated in the FDA indication.
Clinical takeaway. Clinical role: ClariCT.AI assists radiologists and specialists by denoising and enhancing DICOM CT images of the head, chest, heart, and abdomen, including low-dose filtered-back-projection and iterative-reconstruction images, and transmitting processed images to a PACS workstation.
Evidence takeaway. Evidence from the reviewed source record: The FDA summary describes nonclinical system, performance, phantom, and risk-based safety testing and states clinical studies were not required to demonstrate substantial equivalence.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
ClariCT.AI assists radiologists and specialists by denoising and enhancing DICOM CT images of the head, chest, heart, and abdomen, including low-dose filtered-back-projection and iterative-reconstruction images, and transmitting processed images to a PACS workstation.
DICOM CT images, including low-dose filtered-back-projection and iterative-reconstruction images from any CT scanner manufacturer/model within the labeled CT workflow.
The indication is processing and enhancement of CT DICOM images; manufacturer neutrality is stated in the FDA indication.
Exact FDA submission
Checked 2026-09-05
No lesion-detection indication or uniform dose-reduction benefit is inferred. Predicate Zia restrictions in the comparison table are not copied as ClariCT.AI labeling.
The FDA summary describes nonclinical system, performance, phantom, and risk-based safety testing and states clinical studies were not required to demonstrate substantial equivalence.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The FDA summary describes nonclinical system, performance, phantom, and risk-based safety testing and states clinical studies were not required to demonstrate substantial equivalence.
No exact-submission lesion-detection sensitivity with population, endpoint, and threshold was established; denoising quality is not sensitivity.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-05
No exact-submission lesion-detection specificity with population, endpoint, and threshold was established.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
ClariCT.AI K183460 nonclinical verification and validation
DesignNonclinical system, performance, phantom, and safety testing
PopulationPhantom and software inputs; clinical participant count not reported
Scopeexact submission
Tested versionClariCT.AI submitted in K183460; build not stated
IndependenceIndependence not established
K183460
Clinical studies were not required for substantial equivalence according to the summary.
Liver CT Dose Reduction With Deep Learning Based Reconstruction
DesignRegistered prospective multicenter observational cohort with noninferiority comparison
PopulationSuspected focal liver lesions; low-dose CT with ClariCT.AI compared with standard-dose CT using model-based iterative reconstruction.
Scopeproduct family
Tested versionClariCT.AI; exact release and K183460 equivalence not established
Samplen=300
Sites3
IndependenceIndependence not established
NCT05804799
Registry lists 300 actual enrollees, completed status, no posted results, and last update 2023-04-12. Sponsor: Seoul National University Hospital. Enrollment is not an analyzed-cohort count; sponsorship alone does not establish independence.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM CT images, including low-dose filtered-back-projection and iterative-reconstruction images from any CT scanner manufacturer/model within the labeled CT workflow.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Scope: Product family. The baseline on-premises option is supported by current vendor desktop-PC installation information. Embedded and cloud options are also described at family scope; exact 2019 configuration linkage remains unresolved.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Denoised and enhanced CT DICOM images transmitted to a PACS workstation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The baseline on-premises option is supported by current vendor desktop-PC installation information. Embedded and cloud options are also described at family scope; exact 2019 configuration linkage remains unresolved.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
27Fields reviewed
11Source classes checked
0Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads
Both stored trial metadata records screened. NCT05804799 live registry supports a contextual family study without exact-version results. NCT05577884 concerns ultra-low-dose whole-body CT in multiple myeloma; its direct page returned a shell and protocol/version linkage was not established, so no result was promoted. No stored PubMed candidates. The current discovery snapshot contains 0 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not verified - checked 2026-09-05 - Exact FDA submission
CT-to-PACS use is described, but exhaustive patient-age and care-setting eligibility were not established in the reviewed text.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
The product page gives no scoped price. Software, workstation/GPU, installation, support, and upgrade costs need quotation; procurement research is incomplete.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "ClariCT.AI reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-05 - Exact FDA submission
No dated, scoped attestation was reviewed. PHI handling, image-cache retention, access control, audit, and incident-response terms remain unverified.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact FDA submission
Current protocol/noise-setting training and support commitments were not established.
Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission
Dose/protocol-specific acceptance, original/processed image review, update control, and escalation require a site/vendor plan; these are editorial evaluation needs.
Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.
Authorized purpose: Canon Aquilion ONE V2.0 acquires and processes whole-body CT volumes, including head, chest, abdomen, pelvis, cardiac, extremity, inner-ear, and multi-energy examinations with the labeled reconstruction functions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.